Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary and metastatic brain tumors.

Enrico Franceschi1, Luciano Scopece, Stefania Gori

  • 1Medical Oncology, Bellaria Hospital, Bologna, Italy.

Forum (Genoa, Italy)
|July 29, 2006
PubMed
Summary

High-grade malignant gliomas (HGG) remain lethal despite treatment advances. Adjuvant chemotherapy, particularly temozolomide (TMZ), shows survival benefits for newly diagnosed glioblastoma and recurrent HGG, necessitating further research for novel agents and patient selection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The European Association for Neuro-oncology (EANO) Consensus Statement on Radiation Necrosis.

Neuro-oncology·2026
Same author

Educational needs in neuro-oncology: Insights from the European Society for Medical Oncology Central Nervous System Faculty Survey.

Neuro-oncology advances·2026
Same author

Brain tumor susceptibility: From genetic predisposition syndromes to extended characterization of genomic determinants.

Critical reviews in oncology/hematology·2026
Same author

Glioblastoma and PARP inhibitors: the importance of patient selection to maximize therapeutic benefits. A critical review.

Frontiers in oncology·2026
Same author

Ultrasound-Based Therapies in Primary Central Nervous System Tumors.

Cancers·2026
Same author

Closing the Gap: HPV Vaccination and Head and Neck Cancer Prevention.

Current oncology reports·2026

Area of Science:

  • Neuro-oncology
  • Cancer Biology
  • Clinical Trials

Background:

  • High-grade malignant gliomas (HGG) are aggressive primary brain tumors with poor prognoses.
  • Standard treatments include surgery, radiotherapy, and chemotherapy, but outcomes remain limited.
  • Brain metastases are common, particularly from lung, breast, and melanoma cancers, with rising incidence.

Purpose of the Study:

  • To review the efficacy of adjuvant chemotherapy in high-grade malignant gliomas.
  • To discuss treatment strategies for recurrent gliomas and brain metastases.
  • To highlight the need for novel therapeutic agents and molecular predictors of chemosensitivity.

Main Methods:

  • Review of randomized trials and meta-analyses on adjuvant chemotherapy for HGG.

Related Experiment Videos

  • Analysis of treatment outcomes for recurrent HGG, including temozolomide (TMZ).
  • Examination of treatment approaches for brain metastases based on tumor characteristics and disease status.

    • Main Results:

    • Adjuvant chemotherapy, especially nitrosourea-based regimens and temozolomide (TMZ), demonstrates a survival benefit in HGG.
    • Temozolomide (TMZ) shows activity and a favorable toxicity profile in recurrent HGG.
    • Surgery and radiotherapy are indicated for isolated brain metastases in controlled disease; systemic chemotherapy is optimal for chemosensitive tumors.

    Conclusions:

    • Adjuvant chemotherapy, particularly TMZ, improves survival in newly diagnosed and recurrent high-grade malignant gliomas.
    • Effective treatments for patients previously treated with adjuvant TMZ are limited, underscoring the need for new therapies.
    • Molecular studies are crucial for identifying chemosensitivity predictors to optimize patient selection and treatment strategies.